

Jeffrey L Gunter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1347728/publications.pdf>

Version: 2024-02-01

83
papers

8,258
citations

94433

37
h-index

56724

83
g-index

83
all docs

83
docs citations

83
times ranked

10194
citing authors

#	ARTICLE	IF	CITATIONS
1	Development, validation, qualification, and dissemination of quantitative MR methods: Overview and recommendations by the ISMRM quantitative MR study group. <i>Magnetic Resonance in Medicine</i> , 2022, 87, 1184-1206.	3.0	21
2	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. <i>Brain Communications</i> , 2022, 4, fcac017.	3.3	12
3	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	3.3	15
4	Left-Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T 1 Weighted MRI Images. <i>Journal of Magnetic Resonance Imaging</i> , 2022, , .	3.4	3
5	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	11.6	52
6	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 1693-1706.	2.9	44
7	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	4.2	63
8	Association of Initial β -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	9.0	27
9	β -Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , 2021, 96, .	1.1	13
10	A standard system phantom for magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1194-1211.	3.0	44
11	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	2.0	13
12	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. <i>NeuroImage</i> , 2021, 231, 117845.	4.2	38
13	CSF dynamics as a predictor of cognitive progression. <i>NeuroImage</i> , 2021, 232, 117899.	4.2	3
14	Cerebral Microbleeds. <i>Stroke</i> , 2021, 52, 2347-2355.	2.0	9
15	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	4.2	24
16	Relationships between β -amyloid and tau in an elderly population: An accelerated failure time model. <i>NeuroImage</i> , 2021, 242, 118440.	4.2	15
17	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. <i>American Journal of Neuroradiology</i> , 2021, , .	2.4	2
18	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. <i>Neurobiology of Aging</i> , 2021, 110, 27-36.	3.1	7

#	ARTICLE	IF	CITATIONS
19	Linear vs volume measures of ventricle size. <i>Neurology</i> , 2020, 94, e549-e556.	1.1	19
20	β -Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e282-e291.	1.1	65
21	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	7.6	74
22	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. <i>NeuroImage: Clinical</i> , 2020, 28, 102481.	2.7	5
23	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1195-1205.	3.0	30
24	18 F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	3.3	17
25	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	5.3	17
26	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	9.0	182
27	The bivariate distribution of amyloid- β and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	7.6	129
28	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. <i>Stroke</i> , 2019, 50, 3037-3044.	2.0	39
29	Recommendations towards standards for quantitative MRI (qMRI) and outstanding needs. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, e26-e39.	3.4	67
30	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	7.6	33
31	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	7.4	223
32	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. <i>Journal of Neuroimaging</i> , 2019, 29, 624-629.	2.0	9
33	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , 2019, 142, 2483-2491.	7.6	126
34	Neural correlates of domain-specific cognitive decline. <i>Neurology</i> , 2019, 92, e1051-e1063.	1.1	12
35	Entorhinal cortex tau, amyloid- β , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	7.6	68
36	Cerebrospinal fluid dynamics disorders. <i>Neurology</i> , 2019, 93, e2237-e2246.	1.1	19

#	ARTICLE	IF	CITATIONS
37	Association of Longitudinal $\hat{1}^2$ -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	5.9	22
38	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.1	53
39	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	9.0	69
40	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. Journal of Alzheimer's Disease, 2019, 67, 181-195.	2.6	48
41	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	2.7	29
42	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic <i>MAPT</i> mutation carriers. Neurology, 2019, 93, e758-e765.	1.1	18
43	Joint associations of $\hat{1}^2$ -amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	3.1	27
44	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology, 2018, 90, e1404-e1412.	1.1	57
45	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	3.0	34
46	Quantitative magnetic resonance imaging phantoms: A review and the need for a system phantom. Magnetic Resonance in Medicine, 2018, 79, 48-61.	3.0	116
47	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	5.3	49
48	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. Scientific Reports, 2018, 8, 7421.	3.3	9
49	Contributions of imprecision in ¹⁸ F-PET $\hat{1}^2$ -MRI rigid registration to imprecision in amyloid ¹⁸ F-PET $\hat{1}^2$ -SUVR measurements. Human Brain Mapping, 2017, 38, 3323-3336.	3.6	26
50	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	2.4	162
51	$\hat{1}^2$ -tau and $\hat{1}^2$ -amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	5.3	152
52	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127.	4.2	59
53	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex, 2017, 90, 138-148.	2.4	22
54	[P2415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.8	33

#	ARTICLE	IF	CITATIONS
55	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. <i>NeuroImage: Clinical</i> , 2017, 16, 295-302.	2.7	30
56	Effects of hormone therapy on brain structure. <i>Neurology</i> , 2016, 87, 887-896.	1.1	47
57	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. <i>NeuroImage: Clinical</i> , 2016, 11, 802-812.	2.7	249
58	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.1	22
59	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	3.1	20
60	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. <i>Movement Disorders</i> , 2016, 31, 989-994.	3.9	32
61	Cascading network failure across the Alzheimer's disease spectrum. <i>Brain</i> , 2016, 139, 547-562.	7.6	401
62	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 56-64.	10.2	104
63	Effect of intellectual enrichment on AD biomarker trajectories. <i>Neurology</i> , 2016, 86, 1128-1135.	1.1	71
64	Atrial fibrillation, cognitive impairment, and neuroimaging. <i>Alzheimer's and Dementia</i> , 2016, 12, 391-398.	0.8	58
65	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	2.6	27
66	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	2.6	19
67	Does MRI scan acceleration affect power to track brain change?. <i>Neurobiology of Aging</i> , 2015, 36, S167-S177.	3.1	10
68	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2015, 36, 1245-1252.	3.1	83
69	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. <i>Journal of Neurology</i> , 2015, 262, 2064-2072.	3.6	10
70	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	7.6	222
71	Age, Sex, and APOE ϵ 4 Effects on Memory, Brain Structure, and β -Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	9.0	305
72	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	7.6	170

#	ARTICLE	IF	CITATIONS
73	Role of β -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	9.0	23
74	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. <i>NeuroImage</i> , 2015, 123, 149-164.	4.2	63
75	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 452-461.	3.1	113
76	Antemortem MRI findings associated with microinfarcts at autopsy. <i>Neurology</i> , 2014, 82, 1951-1958.	1.1	45
77	Dementia with Lewy bodies. <i>Neurology</i> , 2014, 83, 801-809.	1.1	143
78	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2014, 35, 1483-1490.	3.1	29
79	Age-specific population frequencies of cerebral β -amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	10.2	297
80	^{18}F -fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	3.1	108
81	Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2010, 6, 212-220.	0.8	311
82	The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 685-691.	3.4	2,553
83	Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. <i>NeuroImage</i> , 2005, 26, 600-608.	4.2	169